User profiles for Reed F. Beall
 | Reed F BeallAssistant Professor, University of Calgary Verified email at ucalgary.ca Cited by 932 |
[HTML][HTML] Is patent “evergreening” restricting access to medicine/device combination products?
RF Beall, JW Nickerson, WA Kaplan, A Attaran - PLoS One, 2016 - journals.plos.org
Background Not all new drug products are truly new. Some are the result of marginal innovation
and incremental patenting of existing products, but in such a way that confers no major …
and incremental patenting of existing products, but in such a way that confers no major …
Pre-market development times for biologic versus small-molecule drugs
RF Beall, TJ Hwang, AS Kesselheim - Nature Biotechnology, 2019 - nature.com
3. Regalado, A. More than 26 million people have taken an at-home ancestry test. MIT
Technology Review https://www. technologyreview. com/s/612880/more-than-26-million-…
Technology Review https://www. technologyreview. com/s/612880/more-than-26-million-…
[HTML][HTML] Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997
B Sahragardjoonegani, RF Beall… - … of pharmaceutical policy …, 2021 - Springer
Background Drug repurposing (ie, finding novel uses for existing drugs) is essential for
maximizing medicines’ therapeutic utility, but obtaining regulatory approval for new indications is …
maximizing medicines’ therapeutic utility, but obtaining regulatory approval for new indications is …
[HTML][HTML] A method for approximating future entry of generic drugs
Objectives To develop and test a method for approximating generic entry of top-selling drugs.
Methods The procedure involved 1) identifying products’ key patents as those with a patent …
Methods The procedure involved 1) identifying products’ key patents as those with a patent …
Evaluating the impact of the Orphan Drug Act's seven-year market exclusivity period
For thirty-five years the Orphan Drug Act of 1983 has provided incentives for pharmaceutical
manufacturers to develop drugs to treat rare diseases—conditions that affect fewer than …
manufacturers to develop drugs to treat rare diseases—conditions that affect fewer than …
Patents And Regulatory Exclusivities On Inhalers For Asthma And COPD, 1986–2020: Study examines patents and regulatory exclusivities on inhalers for asthma and …
Inhalers are the mainstay of treatment for asthma and chronic obstructive pulmonary disease
(COPD). These products face limited generic competition in the US and remain expensive. …
(COPD). These products face limited generic competition in the US and remain expensive. …
Patent term restoration for top-selling drugs in the United States
Highlights • Most new drugs receive a patent term restoration (PTR) extension. • Patents
with PTR commonly expire more than 12 years after marketing approval. • Patents with PTR …
with PTR commonly expire more than 12 years after marketing approval. • Patents with PTR …
COVID-19 and the prevalence of drug shortages in Canada: a cross-sectional time-series analysis from April 2017 to April 2022
Background: In March 2020, the Government of Canada introduced measures to reduce
intensifying shortages of prescription drugs during the beginning of the COVID-19 pandemic. …
intensifying shortages of prescription drugs during the beginning of the COVID-19 pandemic. …
The characteristics of patents impacting availability of biosimilars
The large number of biologic drug patents in the United States has contributed to delays in
biosimilar availability.
biosimilar availability.
Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurement
Compulsory licensing has been widely suggested as a legal mechanism for bypassing
patents to introduce lower-cost generic antiretrovirals for HIV/AIDS in developing countries. …
patents to introduce lower-cost generic antiretrovirals for HIV/AIDS in developing countries. …
